Dyax Announces Second Peptide Discovery Collaboration with EPIX Pharmaceuticals
Per the second agreement announced, EPIX may develop and commercialize therapeutic products, in addition to diagnostic products, based on the peptides that Dyax identifies. EPIX will fund Dyax to perform its portion of the research program and will owe development milestone payments to Dyax, as well as royalty payments for a specified period of time upon successful commercialization by EPIX of products based on peptides identified by Dyax.
"We're very pleased to enter into this second collaboration with EPIX. We've established an excellent and productive working relationship that I expect will continue to build and grow. As this agreement with EPIX indicates, our state-of-the-art technology is not limited to the area of antibody discovery, but extends to peptides and small proteins as well - areas that I believe are still relatively untapped as sources of powerful biopharmaceutical products," commented Henry E. Blair, Chairman, President and CEO of Dyax Corp.
Most read news
Topics
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.